Document is current
Any future updates will be listed below
-
Authors
Kwan, Alex C. http://orcid.org/0000-0003-2169-1667
Olson, David E. http://orcid.org/0000-0002-4517-0543
Preller, Katrin H. http://orcid.org/0000-0003-0413-7672
Roth, Bryan L. http://orcid.org/0000-0002-0561-6520
-
Funding
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Institute of Mental Health (R01MH121848, R01MH128217)
Yale Program in Psychedelic Science
U.S. Department of Health & Human Services | NIH | National Institute on Drug Abuse (R01DA056365)
U.S. Department of Health & Human Services | NIH | National Institute of General Medical Sciences (R01GM128997)
Camille and Henry Dreyfus Foundation
United States Department of Defense | Defense Advanced Research Projects Agency
Michael Hooker Distinguished Professorship
- License Information
-
More Information
Article History
Received: 7 December 2021
Accepted: 6 September 2022
First Online: 24 October 2022
Competing interests
: A.C.K. is a member of the Scientific Advisory Board of Empyrean Neuroscience and Freedom Biosciences. A.C.K. has consulted for Biohaven Pharmaceuticals. No-cost compounds were provided to A.C.K. for research by Usona Institute. D.E.O. is a cofounder of Delix Therapeutics, Inc., and serves as the Chief Innovation Officer and Head of the Scientific Advisory Board. K.H.P. is currently an employee of Boehringer Ingelheim GmbH & Co. KG. B.L.R. is a member of the Scientific Advisory Board of Septerna Pharmaceuticals and Escient Pharmaceuticals. These duties had no influence on the content of this article.
